Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2, Open-Label, Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease (AURORA)

Next Previous
Trial Profile

Phase 1/2, Open-Label, Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease (AURORA)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RTX 021 (Primary)
  • Indications Stargardt disease
  • Focus Adverse reactions
  • Acronyms AURORA
  • Sponsors Ray Therapeutics

Most Recent Events

  • 27 Feb 2026 Planned number of patients changed to 18.
  • 27 Feb 2026 Planned End Date changed to 1 Dec 2030.
  • 27 Feb 2026 Planned primary completion date changed to 1 Dec 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top